Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Incidence of osteoarthritis more prevalent among military populations

New research shows significantly higher osteoarthritis (OA) incidence rates in military populations than among comparable age groups in the general population.

30 Jun 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

29 Jun 2011

Diet sodas and artificial sweeteners may not be healthy alternatives

In the constant battle to lose inches or at least stay the same, we reach for the diet soda. Two studies presented June 25 and 27 at the American Diabetes Association's Scientific Sessions in San Diego suggest this might be self-defeating behavior.

29 Jun 2011

Bayer Yakuhin seeks marketing authorization in Japan for EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application to the Ministry of Health, Labor and Welfare (MHLW) in Japan for marketing authorization for EYLEA, also known as VEGF Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

29 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

CEL-SCI Corporation announced today that its partner Teva Pharmaceuticals, a leading global pharmaceutical company, has concluded the Site Initiation Visit for the first Israeli clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy.

27 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Potential new approach for treating myelofibrosis

A new study conducted by a team of researchers at Boston University School of Medicine (BUSM) sheds light on a possible new approach to treat the bone marrow disease known as myelofibrosis by inhibiting an enzyme that connects extracellular fibers.

24 Jun 2011

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.

24 Jun 2011

Scil Technology receives public research grant for novel rheumatoid arthritis treatments

Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF’s KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology’s research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).

23 Jun 2011

Silicone gel-filled breast implants: FDA releases updated data

The U.S. Food and Drug Administration released a report today updating the clinical and scientific information for silicone gel-filled breast implants, including preliminary safety data from studies conducted by the manufacturers as a condition of their November 2006 approval.

23 Jun 2011

Silicone-gel breast implant complications to be watched out for: FDA

The U.S. Food and Drug Administration (FDA) said Wednesday that women receiving silicone-gel breast implants have frequent complications like scarring or hardening breasts, and 20% or more of patients required implant removal within 10 years.

23 Jun 2011

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

A neurological scientist at Rush University Medical Center has received a grant from the National Institutes of Health (NIH) to evaluate whether cinnamon, a common food spice and flavoring material, may stop the destructive process of multiple sclerosis.

23 Jun 2011

Key trigger to rare but deadly neurodegenerative disease

Jeremy Smith, Governor's Chair for Molecular Biophysics at the University of Tennessee, Knoxville, has helped reveal a key trigger of Gerstmann-Str-ussler-Scheinker (GSS) syndrome, a rare but deadly neurodegenerative disease. The finding could have far-reaching implications for the treatment of other neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's.

23 Jun 2011